MP-20.24: Tolterodine extended release (TER) and/or Tamsulosin (TAM) in men with lower urinary tract symptoms (LUTS) including overactive bladder (OAB): effects of prostate size

Roehrborn, Claus G.; Kaplan, S.A.; Jones, J. Stephen; Steers, William D.; Wang, J.T.; Bavendam, Tamara; Guan, Zhonghong

doi:10.1016/j.urology.2007.06.356

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One possible explanation for this discrepancy might be that men were required to meet symptom entry criteria for both OAB and BPH trials and might thus have constituted a study population different from that in most OAB or BPH trials, although not necessarily different from the general population of men with LUTS. In fact, two additional post hoc analyses in which men were stratified by baseline median prostate size [26], or baseline median serum PSA level [27], might suggest that the TIMES study population comprised both men with LUTS resulting primarily from a bladder condition and men with LUTS resulting primarily from prostatic enlargement that might or might not be accompanied by secondary bladder conditions [5,6,9]. These analyses found that tolterodine ER alone effectively improved storage LUTS in men who had smaller prostates (<29 mL) or lower PSA levels (<1.3 ng/mL) but not in men who had larger prostates (≥29 mL) or higher serum PSA levels (≥1.3 ng/mL) at baseline.…”

Section: Discussionmentioning

confidence: 99%

Extended‐release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score

et al. 2008

View full text Add to dashboard Cite

12 weeks. Patients completed the IPSS at baseline and at 1, 6 and 12 weeks. RESULTSPatients receiving tolterodine ER + tamsulosin had significantly greater improvements than those taking placebo on IPSS storage subscale scores and scores for all three individual storage items included on the IPSS (urinary frequency, urgency, and nocturnal micturitions) by 12 weeks. Storage subscale and urgency scores were significantly improved vs placebo at 1 and 6 weeks, whereas frequency scores were significantly improved at 6 weeks. Changes in IPSS storage subscale and individual storage item scores in the tolterodine ER and tamsulosin monotherapy groups were not significantly different from placebo at most time points. IPSS voiding subscale scores and scores for three of four individual voiding items (sensation of incomplete emptying, intermittency, and weak stream) were significantly improved by 12 weeks for patients receiving tamsulosin monotherapy vs placebo. Voiding subscale and intermittency scores were significantly improved vs placebo at 1 week; weak stream scores were significantly improved at 1 and 6 weeks. The IPSS voiding subscale and individual voiding item scores in the tolterodine ER + tamsulosin and tolterodine ER groups were not significantly different from placebo at most time points. CONCLUSIONSIn this distinct clinical research population of men who met traditional symptom entry criteria for both OAB and BPH trials, tolterodine ER + tamsulosin was significantly more effective than placebo in treating storage LUTS, including OAB symptoms. Tamsulosin monotherapy produced significant improvements in voiding LUTS. KEYWORDSoveractive bladder, benign prostatic hyperplasia, lower urinary tract symptoms Study Type -Therapy (RCT) Level of Evidence 1b OBJECTIVETo evaluate the efficacy of tolterodine extended-release (ER) plus tamsulosin on lower urinary tract symptoms (LUTS) as assessed by changes in the International Prostate Symptom Score (IPSS) in men who met symptom entry criteria for both overactive bladder (OAB) and benign prostatic hyperplasia (BPH) trials. PATIENTS AND METHODSMen aged ≥ 40 years with an IPSS of ≥ 12 and diary-documented OAB symptoms ( ≥ 8 voids/ 24 h and ≥ 3 urgency episodes/24 h, with or without urgency urinary incontinence) who reported at least moderate problems related to their bladder condition were randomized to receive placebo, tolterodine ER (4 mg), tamsulosin (0.4 mg), or tolterodine ER (4 mg) + tamsulosin (0.4 mg) once daily for

show abstract

Section: Discussionmentioning

confidence: 99%

Extended‐release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score

et al. 2008

View full text Add to dashboard Cite

show abstract

Urinary Retention and Post-Void Residual Urine in Men: Separating Truth From Tradition

et al. 2008

View full text Add to dashboard Cite

Clinicians are adopting less invasive approaches (eg pharmacology or catheterization) to treating patients who present with the symptoms, sign, and condition of urinary retention. Faced with an abundance of new data on acute urinary retention, urologists need to reach a consensus about the risks of urinary retention; this may promote movement toward patient centered prevention strategies with tailored treatment options.

show abstract

MP-20.24: Tolterodine extended release (TER) and/or Tamsulosin (TAM) in men with lower urinary tract symptoms (LUTS) including overactive bladder (OAB): effects of prostate size

Cited by 2 publications

References 0 publications

Extended‐release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score

Extended‐release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score

Urinary Retention and Post-Void Residual Urine in Men: Separating Truth From Tradition

Contact Info

Product

Resources

About